display
Mainz (dpa) - The corona vaccine manufacturer Biontech claims to have a "complex network of production capacities in Europe".
In addition to the production of the raw material in the company's own plant in Mainz, parts of the production also ran, for example, at partner companies such as Dermapharm near Halle in Saxony-Anhalt and Polymun near Vienna, a company spokeswoman told the German press agency on Monday.
In addition, the vaccine with the name Comirnaty is partly produced and finally bottled in the factory of US partner Pfizer in Puurs, Belgium.
There is also the Pfizer network in the USA.
Biontech boss Ugur Sahin said last week that his company was looking for further partners for production.
At the plant in Marburg, Hesse, which Biontech took over a few weeks ago from the Swiss pharmaceutical giant Novartis, production is scheduled to start in February.
The company is aiming for the release of the first vaccine produced there by the end of March.
It usually takes about four weeks between production and release of the controlled vaccine.
In the first half of 2021, 250 million vaccine doses are to be produced in the plant.
The Mainz-based company is aiming for a total of 750 million cans for an annual production.
According to Biontech, each vial in which Comirnaty is delivered contains an amount of vaccine for up to six doses.
Each dose must contain 0.3 milliliters of the vaccine.
In order to achieve the maximum possible amount of six doses per bottle, however, special syringes and needles are necessary.
Since these are not available everywhere in the world, the bottles are only intended for five doses and have been approved as such by the EU, for example, the company said.
According to the Federal Ministry of Health, six doses can now be taken from one bottle in Germany.
However, excess vaccine from several vials must not be combined into one dose.
display
Biontech